Cayla

Institut National De La Sante Et De La Recherche Medicale

Invivogen

Kayla Therapeutics

Gérard Tiraby

Daniel Drocourt

Fabienne Vernejoul

Thierry Lioux

Eric Perouzel

Louis Buscail

Arnaud Debin

Jean Paul Reynes

Christiane Susini

Céline Casteran

Jean-Paul Reynes

The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy

A synthetic gene devoid of CpG nucleotide derived by genetic engineering from copepod luciferases genes that code for a new secreted luciferase with a strong bioluminescent signal. This gene display advantageous properties to be used as a reporter genes in cell based assays.

CPG-free gene for a new secreted reporter protein

Growing community of inventors

Toulouse, France

Gérard Tiraby